Holen Sie sich die Stockscreener-App
12.89
1.86%
-0.27
Schlusskurs vom Vortag:
$13.16
Offen:
$13.09
24-Stunden-Volumen:
27,502
Relative Volume:
0.05
Marktkapitalisierung:
$221.76M
Einnahmen:
$13.11M
Nettoeinkommen (Verlust:
$-124.02M
KGV:
-0.9039
EPS:
-14.261
Netto-Cashflow:
$-107.25M
1W Leistung:
-3.48%
1M Leistung:
+7.36%
6M Leistung:
-7.35%
1J Leistung:
-49.98%
1-Tages-Spanne:
$12.89
$13.12
1-Wochen-Bereich:
$12.57
$13.60
52-Wochen-Spanne:
$9.40
$31.55
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
12.93 | 225.71M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
522.04 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
799.73 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.27 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
symbol__ Stock Quote Price and Forecast - cnn.com
Tonix Pharmaceuticals Promotes Thomas Englese to Chief Commercial Officer - Minichart
TNXP Looks 393.2% Overvalued on GF Value™ - GuruFocus
Tonix Pharmaceuticals Holding Corp. Announces Appointment of Thomas Englese to Chief Commercial Officer, Effective September 8, 2026 - marketscreener.com
Why is Tonix Pharmaceuticals (NASDAQ:TNXP) stock in focus as Wall Street reopens today? - kalkinemedia.com
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer - GlobeNewswire
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Price-Driven Insight from (TNXP) for Rule-Based Strategy - Stock Traders Daily
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
TNXP|Tonix Pharmaceuticals Holding Corp|Price:13.140|Chg%:-0.230 - TradingKey
TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26 - Yahoo Finance
Tonix CEO will speak at a healthcare conference Sept. 10 - Stock Titan
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock - MarketBeat
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock - Investing.com
Tonix Pharma (NASDAQ: TNXP) CEO adds 2,000 shares in IRA - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen - MarketBeat
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com Canada
Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) Director Purchases $12,600.00 in Stock - MarketBeat
Tonix (TNXP) Market: Adds 1.29% to Close at $12.55; the Near-Term Reference Band Stretches From $11.92 to $13.18 in the Latest ReadingPositive Gamma - siam.in
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript - AOL.com
Tonix (TNXP) Daily Snapshot: Finishes 0.16% Higher at $12.68 in Latest Trading; the $12.05 to $13.31 Range Remains in Focus under the Current SnapshotValue Area High - Vinanet
Why TNXP Stock Is Suddenly Back On Retail Radar - stocktwits.com
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline - MarketBeat
Tonix Pharmaceuticals (TNXP) Holds Ground at $12.66 as Traders Eye $13.29 ResistanceTrend Reversal Picks - vinanet.vn
Tonix Pharmaceuticals Holding Corp. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TNXP) 2026-08-14 - Seeking Alpha
Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants - Stock Titan
AQR Capital discloses 5.54% ownership in Tonix Pharmaceuticals (TNXP) via Schedule 13G - Stock Titan
TNXP Q2 2026 Earnings: Better-Than-Expected Loss per Share, Shares Dip 3%Guidance Accuracy Score - Vinanet
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Tonix Pharmaceuticals Holding Corp.Common Stock (NQ: TNXP - FinancialContent
Industry Analysts Just Made A Dazzling Upgrade To Their Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Revenue Forecasts - Moomoo
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price, news, quote and history - Yahoo Finance UK
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build By Investing.com - Investing.com UK
Tonix Pharmaceuticals (TNXP) Revenue Surge Meets Persistent Cash Burn Concerns - simplywall.st
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build - Investing.com India
Tonix Pharmaceuticals: TONMYA Refills Surge 207% As Coverage Reaches 136 Million U.S. Lives - Pulse 2.0
Tonix Pharma earnings beat by $0.27, revenue topped estimates - Investing.com Nigeria
Tonix Delivers A Beat, But The Real Test Starts Now (NASDAQ:TNXP) - Seeking Alpha
Raymond James raises Tonix Pharma stock price target on strong sales - Investing.com UK
Penny Stocks: What Does Tonix Pharmaceuticals (NASDAQ:TNXP) Update Signal? - Kalkine Media
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Cal - GuruFocus
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ... - Yahoo Finance UK
Tonix Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Tonix Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):